Pharma company Lupin today informed the Bombay Stock Exchange that the company has received US Food and Drug Administration (USFDA) approval for the company's abbreviated new drug application for Ramipril capsules, 1.25 mg, 2.5 mg, 5 mg and 10 mg.


</p><tr><td><p class='TableClas'></p><P class='TableClas'> <DIV CLASS=rightDiv><script language="JavaScript">
		google_ad_client = 'businessstandard';
		//google_ad_client = 'ca-businessstandard_js';
		google_ad_width = 200;
		google_ad_height = 200;
		google_ad_format = "200x200_as";
		google_ad_type = "text";
		google_ad_channel = "";
		//google_color_border = "FFFFFF";
		google_color_border = "F7F7F7";
		//google_color_bg = "FFFFFF";
		google_color_bg = "ffffff";
		//google_color_link = "639ACE";
		google_color_link = "0253B7";
		google_color_text = "000000";
		google_color_url = "D63431";
		//google_skip = adsenseSkip;
		</script> 
		<script type="text/javascript" src="http://pagead2.googlesyndication.com/pagead/show_ads.js">
		</script> </DIV><p class='TableClas'>Commercial shipments of the product has commenced. Ramipril had annual sales of&nbsp; $920 million for the twelve months ended December 2007, based on IMS Health sales data. </P>
</p><p class='TableClas'>Lupin's Ramapril capsules are the AB-rated generic equivalent of King Pharmaceutical's Altace capsules, indicated for the treatment of hypertension. </P>
</p><p class='TableClas'>On June 5, in an effort to restrict Lupin's launch, King filed a motion for a temporary restraining order (TRO) and preliminary injunction against Lupin Pharmaceuticals. </P>
</p><p class='TableClas'>The hearing occurred on June 10 and King's motion was denied, it said.&nbsp;&nbsp; </P></p></table>


Lupin recieves USFDA approval for ramipril

More From This Section

Posco land acquisition resumes amid protests

Diageo to buy half of Mallya's South Africa beer biz

Average money spent for new players dips

'IndiGo did not comply with AAC guidelines'

Explore News